Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Prostatic Neoplasms 22Breast Neoplasms 21Polycystic Ovary Syndrome 12Carcinoma, Non-Small-Cell Lung 11Colorectal Neoplasms 10Lung Neoplasms 8Endometrial Neoplasms 7Pancreatic Neoplasms 6Neoplasms 6Glioblastoma 5Rectal Neoplasms 4Melanoma 4Lymphoma, Large B-Cell, Diffuse 4Insulin Resistance 4Adenocarcinoma of Lung 4Adenocarcinoma 4Uterine Cervical Neoplasms 3Leukoplakia, Oral 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Obesity 2Neoplasm Metastasis 2Liver Neoplasms 2Leukemia, Myeloid, Acute 2Hyperandrogenism 2Esophageal Neoplasms 2Erythroplasia 2Endometrial Hyperplasia 2Diabetes Mellitus 2Colonic Neoplasms 2

Interventions

Dexamethasone 11Lenalidomide 9Calcium Dobesilate 5carfilzomib 4daratumumab 3isatuximab 2iberdomide 2elotuzumab 2dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Leflunomide 2Denosumab 2selinexor 1pomalidomide 1piperine 1ixazomib 1ibrutinib 1fludarabine phosphate 1fludarabine 1Simvastatin 1Nivolumab 1Metformin 1Melphalan 1IPH-2101 1Gene Expression Profiling 1Fatty Acids, Omega-3 1Cyclophosphamide 1Curcumin 1Cholestyramine Resin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Smoldering Multiple Myeloma × Metformin × Clear all
NCT04850846 2026-02-09

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
60 enrolled 10 charts
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance

Data powered by HemOnc (CC BY 4.0) Colophon âš¡